Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#21 / 200 Total
FTEL - Fitell Corp - Stock Price Chart
TickerFTEL [NASD]
CompanyFitell Corp
CountryAustralia
IndustrySpecialty Retail
Market Cap102.75MEPS (ttm)-0.38
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S26.55EPS next 5Y-
P/B10.31EPS Q/Q-4416.98%
Dividend-Sales Q/Q-30.48%
Insider Own57.91%Inst Own0.10%
Insider Trans0.00%Inst Trans-
Short Float2.63%Earnings-
Analyst Recom-Target Price-
Avg Volume582.27K52W Range0.88 - 9.90
Fitell Corp. is an online retailer of gym and fitness equipment. Its brands include Muscle Motion, Rapid Motion, and FleetX. The company was founded in 2007 and is headquartered in Sydney, Australia.
DZSI - DZS Inc - Stock Price Chart
TickerDZSI [NASD, RUT]
CompanyDZS Inc
CountryUSA
IndustryCommunication Equipment
Market Cap40.79MEPS (ttm)-1.76
P/E-EPS this Y1.32%
Forward P/E25.40EPS next Y-87.01%
PEG-EPS past 5Y-
P/S0.10EPS next 5Y20.00%
P/B0.31EPS Q/Q-398.55%
Dividend-Sales Q/Q17.88%
Insider Own46.95%Inst Own22.90%
Insider Trans0.00%Inst Trans-
Short Float7.45%Earnings-
Analyst Recom1.00Target Price6.50
Avg Volume134.81K52W Range0.95 - 7.43
DZS, Inc. engages in the provision of packet-based mobile transport and broadband access solutions. It includes the research, development, test, sale, manufacture, and support of communications equipment in the following areas: broadband access, Ethernet switching, mobile front haul and back haul, passive optical LAN, and software defined networks (SDN) and network function virtualization (NFV) solutions. The company was founded in June 1999 and is headquartered in Plano, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alonso MiguelChief Product OfficerJun 10 '23Option Exercise0.006,250019,039Jun 13 02:59 PM
Ferguson Justin K.Chief Legal OfficerJun 10 '23Option Exercise0.0012,500038,797Jun 13 02:57 PM
VOGT CHARLES DPresident & CEOJun 10 '23Option Exercise0.0014,8160109,068Jun 13 02:56 PM
Kawecki Misty DawnChief Financial OfficerMay 30 '23Option Exercise0.004,138026,245Jun 01 04:56 PM
VOGT CHARLES DPresident & CEOMay 30 '23Option Exercise0.0018,3910102,096Jun 01 04:54 PM
ASRT - Assertio Holdings Inc - Stock Price Chart
TickerASRT [NASD, RUT]
CompanyAssertio Holdings Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap116.05MEPS (ttm)-3.97
P/E-EPS this Y-121.82%
Forward P/E244.00EPS next Y104.17%
PEG-EPS past 5Y-
P/S0.76EPS next 5Y25.00%
P/B0.84EPS Q/Q-145.92%
Dividend-Sales Q/Q-34.49%
Insider Own5.92%Inst Own50.87%
Insider Trans-0.18%Inst Trans11.52%
Short Float12.02%EarningsMay 06/a
Analyst Recom1.00Target Price3.00
Avg Volume959.75K52W Range0.73 - 8.01
Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tyree James LDirectorMar 14 '24Sale1.1210,25111,463188,251Mar 15 08:01 PM
Schlessinger SamSVP, General CounselFeb 21 '24Option Exercise0.0017,1510109,384Feb 23 05:32 PM
Patel AjaySVP and CFOFeb 21 '24Option Exercise0.0017,1510141,760Feb 23 05:30 PM
Schwichtenberg PaulSVP, CCOFeb 21 '24Option Exercise0.0017,1510112,430Feb 23 05:31 PM
Schwichtenberg PaulSee RemarksFeb 11 '24Option Exercise0.0047,3480111,661Feb 13 07:01 PM
BCRX - Biocryst Pharmaceuticals Inc. - Stock Price Chart
TickerBCRX [NASD, RUT]
CompanyBiocryst Pharmaceuticals Inc.
CountryUSA
IndustryBiotechnology
Market Cap1.09BEPS (ttm)-1.18
P/E-EPS this Y42.13%
Forward P/E-EPS next Y45.04%
PEG-EPS past 5Y-3.73%
P/S3.28EPS next 5Y44.80%
P/B-EPS Q/Q19.91%
Dividend-Sales Q/Q17.42%
Insider Own3.68%Inst Own83.71%
Insider Trans0.00%Inst Trans-1.64%
Short Float17.30%EarningsMay 06/b
Analyst Recom1.33Target Price14.00
Avg Volume3.25M52W Range4.03 - 8.96
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SANDERS MACHELLEDirectorJun 15 '23Sale7.984,00031,92025,611Jun 15 04:37 PM
Hutson Nancy JDirectorJun 14 '23Sale8.0412,866103,44381,818Jun 15 04:33 PM
MARA - Marathon Digital Holdings Inc - Stock Price Chart
TickerMARA [NASD, RUT]
CompanyMarathon Digital Holdings Inc
CountryUSA
IndustryCapital Markets
Market Cap5.84BEPS (ttm)1.12
P/E18.39EPS this Y-103.00%
Forward P/E50.78EPS next Y1201.87%
PEG0.37EPS past 5Y-
P/S15.08EPS next 5Y50.00%
P/B3.11EPS Q/Q130.53%
Dividend-Sales Q/Q451.67%
Insider Own1.68%Inst Own37.38%
Insider Trans0.00%Inst Trans-3.00%
Short Float18.89%EarningsMay 09/a
Analyst Recom2.40Target Price25.19
Avg Volume62.09M52W Range7.16 - 34.09
Marathon Digital Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the blockchain ecosystem and the generation of digital assets. The company was founded on February 23, 2010 and is headquartered in Las Vegas, NV.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SWAMI ASHUDirectorAug 31 '23Sale13.8011,000151,8337,491Sep 01 07:11 PM
Ouissal SaidDirectorAug 23 '23Sale11.805,00059,00010,217Aug 25 07:00 PM
Ouissal SaidDirectorAug 22 '23Sale10.9515,000164,25015,217Aug 23 09:25 PM
MTEN - Mingteng International Corporation Inc - Stock Price Chart
TickerMTEN [NASD]
CompanyMingteng International Corporation Inc
CountryChina
IndustryMetal Fabrication
Market Cap32.73MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume239.84K52W Range3.00 - 4.79
Mingteng International Corp., Inc. is a holding company that engages in the manufacture, design, development, assembly, and supply sale of automotive mold. It operates under the following segments: Mold Production, Mold Repair, and Machining Services. The company was founded on September 20, 2021 and is headquartered in Wuxi, China.
ZVSA - ZyVersa Therapeutics Inc - Stock Price Chart
TickerZVSA [NASD]
CompanyZyVersa Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap4.86MEPS (ttm)-71.31
P/E-EPS this Y98.62%
Forward P/E-EPS next Y-206.98%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.23EPS Q/Q-6291.81%
Dividend-Sales Q/Q-
Insider Own1.17%Inst Own13.75%
Insider Trans0.00%Inst Trans-
Short Float6.14%EarningsMar 25/b
Analyst Recom1.00Target Price70.00
Avg Volume394.64K52W Range4.44 - 220.85
Apr-29-24 07:57AM ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease (GlobeNewswire) +15.63%
Apr-04-24 07:57AM ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes (GlobeNewswire)
Mar-25-24 08:17AM ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-18-24 07:57AM ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease (GlobeNewswire) +8.79%
Mar-14-24 07:57AM ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024 (GlobeNewswire)
Feb-29-24 07:57AM ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity (GlobeNewswire) +10.00%
Feb-28-24 07:57AM ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications (GlobeNewswire) -8.26%
Feb-26-24 07:55AM Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today? (InvestorPlace) +34.83%
Feb-22-24 07:47AM ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option (GlobeNewswire)
Feb-14-24 07:53AM ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases (GlobeNewswire)
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.
BNAI - Brand Engagement Network Inc - Stock Price Chart
TickerBNAI [NASD]
CompanyBrand Engagement Network Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap62.31MEPS (ttm)-0.00
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.79EPS Q/Q-197.91%
Dividend-Sales Q/Q-
Insider Own54.10%Inst Own5.51%
Insider Trans0.00%Inst Trans5.83%
Short Float0.11%Earnings-
Analyst Recom-Target Price-
Avg Volume95.66K52W Range1.42 - 19.75
Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is headquartered in Jackson, WY.
LOCL - Local Bounti Corp - Stock Price Chart
TickerLOCL [NYSE]
CompanyLocal Bounti Corp
CountryUSA
IndustryFarm Products
Market Cap25.74MEPS (ttm)-12.71
P/E-EPS this Y49.87%
Forward P/E-EPS next Y40.13%
PEG-EPS past 5Y-
P/S0.93EPS next 5Y-
P/B1.66EPS Q/Q-110.13%
Dividend-Sales Q/Q3.43%
Insider Own62.19%Inst Own10.82%
Insider Trans0.05%Inst Trans-
Short Float2.50%EarningsMar 27/b
Analyst Recom1.00Target Price8.00
Avg Volume13.14K52W Range1.17 - 7.18
Local Bounti Corp. operates as an advanced indoor growing facility. It is a premier Controlled Environment Agriculture (CEA) company redefining conversion efficiency and environmental, social and governance standards for indoor agriculture. The company was founded by Travis Joyner and Craig M. Hurlbert in August 2018 and is headquartered in Hamilton, MT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nelson Mark JosephDirectorApr 15 '24Sale2.316601,52830,388Apr 17 05:14 PM
Nelson Mark JosephDirectorMar 13 '24Sale2.594471,15931,048Mar 15 05:53 PM
VALIASEK KATHLEENChief Financial OfficerNov 13 '23Buy3.178002,540273,686Nov 13 06:35 PM
VALIASEK KATHLEENChief Financial OfficerNov 10 '23Buy2.827001,974272,886Nov 13 06:35 PM
Vosburg B. DavidChief Innovation OfficerNov 09 '23Sale3.884,25016,471106,023Nov 09 04:53 PM
DMAC - DiaMedica Therapeutics Inc - Stock Price Chart
TickerDMAC [NASD]
CompanyDiaMedica Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap132.86MEPS (ttm)-0.62
P/E-EPS this Y-18.33%
Forward P/E-EPS next Y-16.90%
PEG-EPS past 5Y4.28%
P/S-EPS next 5Y30.00%
P/B2.60EPS Q/Q4.09%
Dividend-Sales Q/Q-
Insider Own37.35%Inst Own10.58%
Insider Trans0.14%Inst Trans-10.64%
Short Float0.74%EarningsMay 08/a
Analyst Recom1.00Target Price7.00
Avg Volume38.37K52W Range1.58 - 4.75
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wambeke David J.Chief Business OfficerNov 16 '23Buy2.4620,00049,200527,114Nov 16 04:37 PM
Von Koch Thomas10% OwnerJun 23 '23Buy3.401,470,5884,999,9994,326,435Jun 27 04:11 PM
Giuffre Randall MichaelDirectorJun 23 '23Buy3.9165,000254,150360,355Jun 26 04:42 PM
Wambeke David J.Chief Business OfficerJun 23 '23Buy3.9138,364150,003507,114Jun 26 04:14 PM
Pilnik Richard D.DirectorJun 23 '23Buy3.9138,363149,999248,245Jun 26 04:03 PM
123456781020